These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 24562617)

  • 1. B cell suppression in newborn following treatment of pregnant diffuse large B-cell lymphoma patient with rituximab containing regimen.
    Mandal PK; Dolai TK; Bagchi B; Ghosh MK; Bose S; Bhattacharyya M
    Indian J Pediatr; 2014 Oct; 81(10):1092-4. PubMed ID: 24562617
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Peripheral blood lymphocyte/monocyte ratio predicts outcome in follicular lymphoma and in diffuse large B-cell lymphoma patients in the rituximab era.
    Belotti A; Doni E; Bolis S; Rossini F; Casaroli I; Pezzatti S; Pogliani EM; Pioltelli PE
    Clin Lymphoma Myeloma Leuk; 2015 Apr; 15(4):208-13. PubMed ID: 25468321
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluation of clinical and biological prognostic factors in relapsed or refractory diffuse large B-cell lymphoma patients after previous treatment with rituximab and chemotherapy: results of the PRO-R-IPI study.
    Panizo C; Rodríguez AJ; Gutiérrez G; Díaz FJ; González-Barca E; de Oña R; Grande C; Sancho JM; García-Álvarez MF; Sánchez-González B; Peñalver FJ; Cannata J; Espeso M; Requena MJ; Gardella S; Durán S; González AP; Alfonso A; Caballero MD;
    Clin Lymphoma Myeloma Leuk; 2015 Jul; 15(7):398-403. PubMed ID: 25843416
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Maternal and neonatal outcomes in 80 patients diagnosed with non-Hodgkin lymphoma during pregnancy: results from the International Network of Cancer, Infertility and Pregnancy.
    Maggen C; Dierickx D; Cardonick E; Mhallem Gziri M; Cabrera-Garcia A; Shmakov RG; Avivi I; Masturzo B; Duvekot JJ; Ottevanger PB; O'Laughlin A; Polushkina E; Van Calsteren K; Woei-A-Jin FJSH; Amant F;
    Br J Haematol; 2021 Apr; 193(1):52-62. PubMed ID: 32945547
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Primary mediastinal large B-cell lymphoma in pregnant women].
    Mangasarova IaK; Bariakh EA; Vorob'ev VI; Khlavno AB; Magomedova AU; Shmakov RG; Kravchenko SK
    Ter Arkh; 2014; 86(7):53-8. PubMed ID: 25314778
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dysfunctional Immune System Reconstitution After Rituximab Exposure In Utero.
    Clark R; Lindsey D; Whiteway S; Mikita C; Lieuw K
    J Pediatr Hematol Oncol; 2021 May; 43(4):e601-e604. PubMed ID: 32590421
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The effects of erythropoiesis-stimulating agents on the management of chemotherapy-induced anemia and tumor growth in diffuse large B-cell lymphoma patients.
    Park LC; Song YJ; Kim DJ; Kim MJ; Jo JC; Lee WS; Shin HJ; Oh SY; Do YR; Jeong JY; Lee HS;
    Int J Cancer; 2019 Nov; 145(9):2459-2467. PubMed ID: 30973963
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Adaptive B cell responses in rituximab-treated diffuse large B cell lymphoma patients during complete remission.
    Cha Z; Li C; Zang Y; Gu H; Guo H; Li J; Fang Y; Petersen TF; Li J; Karas RO; Hamilton ML; Qian B
    Tumour Biol; 2016 Jan; 37(1):829-35. PubMed ID: 26254098
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Non-Hodgkin lymphomas: impact of rituximab on overall survival of patients with diffuse large B-cell and follicular lymphoma.
    Jaime-Pérez JC; Gamboa-Alonso CM; Vázquez-Mellado de Larracoechea A; Rodríguez-Martínez M; Gutiérrez-Aguirre CH; Marfil-Rivera LJ; Gómez-Almaguer D
    Arch Med Res; 2015 Aug; 46(6):454-61. PubMed ID: 26235285
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Subsequent primary malignancies after diffuse large B-cell lymphoma in the modern treatment era.
    Tao L; Clarke CA; Rosenberg AS; Advani RH; Jonas BA; Flowers CR; Keegan THM
    Br J Haematol; 2017 Jul; 178(1):72-80. PubMed ID: 28542862
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Low absolute lymphocyte count and addition of rituximab confer high risk for interstitial pneumonia in patients with diffuse large B-cell lymphoma.
    Huang YC; Liu CJ; Liu CY; Pai JT; Hong YC; Teng HW; Hsiao LT; Chao TC; Gau JP; Liu JH; Hsu HC; Chiou TJ; Chen PM; Yu YB; Tzeng CH
    Ann Hematol; 2011 Oct; 90(10):1145-51. PubMed ID: 21647583
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Successful treatment with preceding low-intensity chemotherapy in a primary mediastinal large B cell lymphoma patient diagnosed at 11 weeks of pregnancy].
    Hattori D; Yahagi Y; Uryu H; Hosoba R; Momoki M; Nagao R; Yamazaki H
    Rinsho Ketsueki; 2019; 60(2):112-117. PubMed ID: 30842377
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Successful Management of Primary Mediastinal Large B-cell Lymphoma during Pregnancy.
    Hashimoto Y; Omura H; Tokuyasu Y; Nakamoto S; Tanaka T
    Intern Med; 2019 Dec; 58(23):3455-3459. PubMed ID: 31391392
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Economic burden and treatment patterns for patients with diffuse large B-cell lymphoma and follicular lymphoma in the USA.
    Ren J; Asche CV; Shou Y; Galaznik A
    J Comp Eff Res; 2019 Apr; 8(6):393-402. PubMed ID: 30855175
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ibrutinib plus lenalidomide and rituximab has promising activity in relapsed/refractory non-germinal center B-cell-like DLBCL.
    Goy A; Ramchandren R; Ghosh N; Munoz J; Morgan DS; Dang NH; Knapp M; Delioukina M; Kingsley E; Ping J; Beaupre DM; Neuenburg JK; Ruan J
    Blood; 2019 Sep; 134(13):1024-1036. PubMed ID: 31331917
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and safety of a combined rituximab chemotherapy during pregnancy.
    Herold M; Schnohr S; Bittrich H
    J Clin Oncol; 2001 Jul; 19(14):3439. PubMed ID: 11454895
    [No Abstract]   [Full Text] [Related]  

  • 17. [Chemotherapy in the second and third trimester of pregnancy is compatible with the delivery of a healthy infant].
    Pedersen BW; Clausen MB; Gørløv JS; Langhoff-Roos J; Storgaard L
    Ugeskr Laeger; 2015 Jun; 177(23):V12140713. PubMed ID: 26058439
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Preference for subcutaneous or intravenous administration of rituximab among patients with untreated CD20+ diffuse large B-cell lymphoma or follicular lymphoma: results from a prospective, randomized, open-label, crossover study (PrefMab).
    Rummel M; Kim TM; Aversa F; Brugger W; Capochiani E; Plenteda C; Re F; Trask P; Osborne S; Smith R; Grigg A
    Ann Oncol; 2017 Apr; 28(4):836-842. PubMed ID: 28031173
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Rituximab plus chemotherapy as first-line treatment in Chinese patients with diffuse large B-cell lymphoma in routine practice: a prospective, multicentre, non-interventional study.
    Wu J; Song Y; Su L; Xu L; Chen T; Zhao Z; Zhang M; Li W; Hu Y; Zhang X; Gao Y; Niu Z; Feng R; Wang W; Peng J; Li X; Ouyang X; Wu C; Zhang W; Zeng Y; Xiao Z; Liang Y; Zhuang Y; Wang J; Sun Z; Bai H; Cui T; Feng J
    BMC Cancer; 2016 Jul; 16():537. PubMed ID: 27460571
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Peripheral Blood Lymphocyte-to-Monocyte Ratio at Relapse Predicts Outcome for Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma in the Rituximab Era.
    Katoh D; Ochi Y; Yabushita T; Ono Y; Hiramoto N; Yoshioka S; Yonetani N; Matsushita A; Hashimoto H; Kaji S; Imai Y; Ishikawa T
    Clin Lymphoma Myeloma Leuk; 2017 Dec; 17(12):e91-e97. PubMed ID: 28918104
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.